The post‐operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty

Abstract

Lumiracoxib is an effective alternative to traditional non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of post-operative pain.

A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain

“…Moreover, it was reported to be as effective as a high dose of naproxen, which is considered to be a very effective analgesic. These findings are consistent with observations by Chan et al (15), who reported that lumiracoxib 400 mg qd had comparable analgesic efficacy to naproxen 500 mg bid in patients with acute pain following arthroplasty. Finally, the reduction in pain intensity was similar between treatments in both mornings and evenings, indicating that lumiracoxib provided effective analgesia despite only qd dosing.…”

“…There have been no previously published studies investigating the efficacy of the selective COX‐2 inhibitor, lumiracoxib, in acute musculoskeletal pain. However, lumiracoxib 400 mg qd has been shown to be effective at relieving acute moderate‐to‐severe pain following arthroplastic surgery (15), dental surgery (16,18) or associated with primary dysmenorrhoea (20). This current study demonstrates that lumiracoxib 400 mg qd is also an effective analgesic in patients with acute pain from uncomplicated soft tissue injuries, such as sprains and strains.…”

Reducing the Pain: A Systematic Review of Postdischarge Analgesia Following Elective Orthopedic Surgery

“…Naproxen use also reduced pain intensity [43,45] and rescue analgesia consumption [43,44] following therapeutic arthroscopic procedures. One study demonstrated a reduction in the pain intensity difference, but not in pain intensity or rescue analgesia consumption, in the intervention group [46]. Adverse event frequency across all studies was high, with a significant increase for the intervention group after the first week following arthroscopic partial meniscectomy [43].…”

“…Compared with a placebo, naproxen was more likely to relieve pain following arthroscopic knee procedures [43–45] and total knee or hip arthroplasty [46]. Naproxen use also reduced pain intensity [43,45] and rescue analgesia consumption [43,44] following therapeutic arthroscopic procedures.…”

Lumiracoxib 400 mg Compared With Celecoxib 400 mg and Placebo for Treating Pain Following Dental Surgery: A Randomized, Controlled Trial

“…19 However, lumiracoxib also differs from other selective COX-2 inhibitors in that it is acidic, which promotes its preferential distribution into inflamed tissue, 1,8,22 where concentrations outlast those in the circulation, and allows once-daily administration. 1,19 Lumiracoxib has been developed for the treatment of osteoarthritis (OA) 21 and the management of moderateto-severe acute pain after knee or hip arthroplasty, 3 dental surgery, 11 uncomplicated soft-tissue injuries, 12 and primary dysmenorrhea, 10 as well as pain associated with acute gout. 23 The analgesic efficacy of lumiracoxib in patients with moderate-to-severe dental pain after extraction of Ն2 impacted third molars has been investigated in several comparator trials.…”